ReviewAntioxidants (Basel, Switzerland)2021
Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review.
Review in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 1 synthesis or guideline pooled it, 167 citations in OpenAlex.
- Non-alcoholic fatty liver disease and coexisting depression, anxiety and/or stress in adults: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Integrated transcriptome and metabolome revealVirulence · 2026Article
- Bioinformatics and experimental validation of druggable targets in non-alcoholic fatty liver disease.Scientific reports · 2026Article
- Rehabilitation challenges and enablers for exercise in post-liver transplant patients with metabolic syndrome: a qualitative study.BMC nursing · 2026Article
- Article
- Perceived Barriers to a Healthy Diet and Factors Associated With Unhealthy Food Consumption in Steatotic Liver Disease.Gastro hep advances · 2026Article
- Article
- Chemerin Normal Function and Roles in Metabolic and Nonmetabolic Disorders: An Up-To-Date Comprehensive Review.Biochemistry research international · 2026Review
- Dose-response association between metabolic syndrome component count and metabolic dysfunction-associated fatty liver disease, and independent graded association of visceral fat area: a cross-sectional study in a health-checkup population.Frontiers in public health · 2026Article
- Article
- Metabolic Syndrome and Insulin Resistance Are Associated With Normal-Range Aspartate Aminotransferase, Alanine Aminotransferase, and Their Ratio in Chinese Women With Polycystic Ovary Syndrome.Clinical endocrinology · 2025Article
- Article
- Toxins to treatments: Impact of environmental pollutants, gut microbiota, and natural compounds on non-alcoholic fatty liver disease progression.World journal of hepatology · 2025Review
- Narrative review of metabolic syndrome and its relationships with non-alcoholic fatty liver disease, gonadal dysfunction and obstructive sleep apnea.Diabetology & metabolic syndrome · 2025Review
- Nanocarrier-enabled delivery of natural antiobesity agents.Nanomedicine (London, England) · 2025Review
- Association between Dietary Index for Gut Microbiota (DI-GM) and non-alcoholic fatty liver disease (NAFLD): Evidence from NHANES 1999-2018.Asia Pacific journal of clinical nutrition · 2025Observational
- Exercise self-efficacy in older adults with metabolic-associated fatty liver disease: A latent profile analysis.Sports medicine and health science · 2025Article
- A machine learning-based framework for predicting metabolic syndrome using serum liver function tests and high-sensitivity C-reactive protein.Scientific reports · 2025Article
- Effects of Curcuminoids Plus Piperine Co-Supplementation on Liver Enzymes and Inflammation in Adults: A GRADE-Assessed Systematic Review and Meta-Analysis.Food science & nutrition · 2025Review
- Cardiovascular implications of metabolic dysfunction-associated fatty liver disease and type 2 diabetes mellitus: A meta-analysis.World journal of hepatology · 2025Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) are two different entities sharing common clinical and physio-pathological features, with insulin resistance (IR) as the most relevant. Large evidence leads to consider it as a risk factor for cardiovascular disease, regardless of age, sex, smoking habit, cholesterolemia, and other elements of MS. Therapeutic strategies remain still unclear, but lifestyle modifications (diet, physical exercise, and weight loss) determine an improvement in IR, MS, and both clinical and histologic liver picture. NAFLD and IR are bidirectionally correlated and, consequently, the development of pre-diabetes and diabetes is the most direct consequence at the extrahepatic level. In turn, type 2 diabetes is a well-known risk factor for multiorgan damage, including an involvement of cardiovascular system, kidney and peripheral nervous system. The increased MS incidence worldwide, above all due to changes in diet and lifestyle, is associated with an equally significant increase in NAFLD, with a subsequent rise in both morbidity and mortality due to both metabolic, hepatic and cardiovascular diseases. Therefore, the slowdown in the increase of the "bad company" constituted by MS and NAFLD, with all the consequent direct and indirect costs, represents one of the main challenges for the National Health Systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.